MX2017007272A - Metodos y composiciones para tratar cancer. - Google Patents

Metodos y composiciones para tratar cancer.

Info

Publication number: MX2017007272A
Authority: MX; Mexico
Prior art keywords: methods; cells; il13ra2; variant; compositions
Prior art date: 2014-12-02

Application number

MX2017007272A

Other languages

English (en)

Spanish (es)

Inventor

Sengupta Sadhak

Sampath Prakash

P Junghans Richard

Original Assignee

Roger Williams Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-02

Filing date

2015-12-01

Publication date

2018-06-06

2015-12-01 Application filed by Roger Williams Hospital filed Critical Roger Williams Hospital

2018-06-06 Publication of MX2017007272A publication Critical patent/MX2017007272A/es

Links

238000000034 method Methods 0.000 title abstract 3
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 abstract 2
210000002865 immune cell Anatomy 0.000 abstract 2
239000000203 mixture Substances 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
229960004964 temozolomide Drugs 0.000 abstract 2
101000796998 Bacillus subtilis (strain 168) Methylated-DNA-protein-cysteine methyltransferase, inducible Proteins 0.000 abstract 1
206010018338 Glioma Diseases 0.000 abstract 1
102000003816 Interleukin-13 Human genes 0.000 abstract 1
108090000176 Interleukin-13 Proteins 0.000 abstract 1
102000004559 Interleukin-13 Receptors Human genes 0.000 abstract 1
108010017511 Interleukin-13 Receptors Proteins 0.000 abstract 1
102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
229940127089 cytotoxic agent Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
208000029824 high grade glioma Diseases 0.000 abstract 1
201000011614 malignant glioma Diseases 0.000 abstract 1
238000011275 oncology therapy Methods 0.000 abstract 1
239000002245 particle Substances 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Cell Biology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Oncology (AREA)

MX2017007272A 2014-12-02 2015-12-01 Metodos y composiciones para tratar cancer. MX2017007272A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462086346P	2014-12-02	2014-12-02
PCT/US2015/063267 WO2016089916A1 (en)	2014-12-02	2015-12-01	Methods and compositons for treating cancer

Publications (1)

Publication Number	Publication Date
MX2017007272A true MX2017007272A (es)	2018-06-06

Family

ID=56078487

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2017007272A MX2017007272A (es)	2014-12-02	2015-12-01	Metodos y composiciones para tratar cancer.

Country Status (18)

Country	Link
US (2)	US9650428B2 (2)
EP (1)	EP3227317A4 (2)
JP (1)	JP2017537622A (2)
KR (1)	KR20180041087A (2)
CN (1)	CN107709353A (2)
AR (1)	AR102879A1 (2)
AU (1)	AU2015355084A1 (2)
BR (1)	BR112017011771A2 (2)
CA (1)	CA2969714A1 (2)
EA (1)	EA201791210A1 (2)
HK (1)	HK1251862A1 (2)
IL (1)	IL252610A0 (2)
MX (1)	MX2017007272A (2)
PH (1)	PH12017501031A1 (2)
SG (2)	SG10202103475XA (2)
TW (1)	TW201636425A (2)
UY (1)	UY36418A (2)
WO (1)	WO2016089916A1 (2)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2850093B1 (en)	2012-01-27	2019-01-09	The Board of Trustees of the Leland Stanford Junior University	Therapeutic il-13 polypeptides
IN2015KN00329A (2)	2012-08-09	2015-07-10	Univ Leland Stanford Junior
EP2934532B1 (en)	2012-12-20	2019-10-23	Purdue Research Foundation	Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
WO2015042705A1 (en)	2013-09-24	2015-04-02	Medicenna Biopharma Inc.	Interleukin-4 receptor-binding fusion proteins and uses thereof
SG10202103475XA (en)	2014-12-02	2021-05-28	Prospect Chartercare Rwmc Llc	Methods and compositons for treating cancer
FI3909972T3 (fi)	2015-06-19	2024-05-03	Sebastian Kobold	Pd1-cd28-fuusioproteiineja ja niiden käyttö lääkkeessä
KR102011789B1 (ko) *	2015-08-05	2019-08-19	주식회사 셀랩메드	키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포
JP7282521B2 (ja)	2016-04-08	2023-05-29	パーデュー・リサーチ・ファウンデイション	Ｃａｒｔ細胞療法のための方法および組成物
WO2018112266A1 (en) *	2016-12-14	2018-06-21	The Board Of Trustees Of The Leland Stanford Junior University	Il-13 superkine: immune cell targeting constructs and methods of use thereof
CN110612119B (zh)	2017-02-07	2024-10-29	西雅图儿童医院（Dba西雅图儿童研究所）	磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
JP7178355B2 (ja)	2017-02-28	2022-11-25	エンドサイト・インコーポレイテッド	Ｃａｒｔ細胞療法のための組成物および方法
WO2018195339A1 (en)	2017-04-19	2018-10-25	Board Of Regents, The University Of Texas System	Immune cells expressing engineered antigen receptors
WO2019073299A1 (en)	2017-10-10	2019-04-18	Medicenna Therapeutics, Inc.	IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS
WO2019100079A1 (en) *	2017-11-20	2019-05-23	Prospect CharterCare RWMC, LLC d/b/a Roger Williams Medical Center	Compositions for improving car-t cell functionality and user thereof
KR102752985B1 (ko)	2017-12-20	2025-01-10	포세이다 테라퓨틱스, 인크.	Vcar 조성물 및 사용 방법
JP7549303B2 (ja)	2018-01-22	2024-09-11	エンドサイト・インコーポレイテッド	Ｃａｒｔ細胞の使用方法
US11701405B2 (en) *	2018-01-26	2023-07-18	City Of Hope	Chimeric antigen receptors and methods for reducing toxicity
SG11202007426XA (en)	2018-02-06	2020-09-29	Seattle Childrens Hospital Dba Seattle Childrens Res Inst	Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CN110157674A (zh) *	2018-02-12	2019-08-23	深圳宾德生物技术有限公司	一种靶向性t淋巴细胞及其制备方法和应用
CN110144326A (zh) *	2018-02-12	2019-08-20	深圳宾德生物技术有限公司	一种靶向性抗肿瘤t细胞及其制备方法和应用
JP7273421B2 (ja)	2018-02-21	2023-05-15	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
CN112105382A (zh)	2018-02-23	2020-12-18	恩多塞特公司	用于car t细胞疗法的顺序方法
CN108440674A (zh) *	2018-04-28	2018-08-24	杭州荣泽生物科技有限公司	一种Trop-2特异性嵌合抗原受体细胞制备及其用途
WO2019239213A2 (en)	2018-06-01	2019-12-19	Medicenna Therapeutics Inc.	Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
WO2019232523A1 (en)	2018-06-01	2019-12-05	The Board Of Trustees Of The Leland Stanford Junior University	Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
US12419954B2 (en) *	2020-01-31	2025-09-23	City Of Hope	Targeted chimeric antigen receptor modified T cells for treatment of IL13Rα2 positive malignancies
AU2021217003A1 (en)	2020-02-04	2022-09-15	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Anti-dinitrophenol chimeric antigen receptors
WO2021241719A1 (ja) *	2020-05-28	2021-12-02	中外製薬株式会社	改良されたグランザイムｂ改変体
CA3193009A1 (en) *	2020-08-26	2022-03-03	The Regents Of The University Of California	Methods and compositions for treating glioblastoma
AU2021342299A1 (en) *	2020-09-11	2023-04-13	The United States Of America, As Represented By The Secretary Of Agriculture	Compositions and methods of use thereof for prevention and treatment of influenza infections
AR124414A1 (es)	2020-12-18	2023-03-22	Century Therapeutics Inc	Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
CN114907485B (zh) *	2021-02-08	2024-04-26	浙江大学	一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
CN113304267B (zh) *	2021-06-11	2022-03-15	河南大学	肺癌的治疗靶点及其应用
CN114014941B (zh) *	2022-01-10	2022-04-12	卡瑞济(北京)生命科技有限公司	靶向IL13Rα2的嵌合抗原受体及其用途
CN116549667B (zh) *	2023-05-29	2024-02-09	四川普锐特药业有限公司	一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5965126A (en) *	1996-03-25	1999-10-12	The Penn State Research Foundation	use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
DE60038622D1 (de) *	1999-10-20	2008-05-29	Univ Johns Hopkins Med	Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
US20030235555A1 (en) *	2002-04-05	2003-12-25	David Shealey	Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
IL163515A0 (en) *	2002-03-01	2005-12-18	Bristol Myers Squibb Co	Transgenic non-human mammals
US7709625B2 (en) *	2004-06-10	2010-05-04	The Board Of Regents Of The University Of Texas	Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy
WO2007075077A1 (es) *	2005-11-16	2007-07-05	Universidad Nacional Autonoma De Mexico	Uso de agentes modificantes del transcriptoma más quimioterapia o radioterapia contra el cáncer
CN101616685B (zh) *	2006-03-06	2013-07-24	阿穆尼克斯运营公司	非结构化重组聚合物和其应用
US20080206139A1 (en) *	2006-11-03	2008-08-28	The Penn State Research Foundation	Delivery system for diagnostic and therapeutic agents
EP4032552B1 (en) *	2008-08-26	2023-10-04	City of Hope	Method and compositions for enhanced anti-tumor effector functioning of t cells
US9273283B2 (en) *	2009-10-29	2016-03-01	The Trustees Of Dartmouth College	Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
PT2552959T (pt) *	2010-03-26	2017-04-21	Memorial Sloan Kettering Cancer Center	Anticorpos para muc16 e métodos de utilização dos mesmos
WO2014090985A1 (en) *	2012-12-13	2014-06-19	Universität Leipzig	T-cell modulation by exon skipping
EP4303232A3 (en) *	2013-02-15	2024-04-17	The Regents of The University of California	Chimeric antigen receptor and methods of use thereof
EP2968601A1 (en) *	2013-03-10	2016-01-20	Baylor College Of Medicine	Chemotherapy-resistant immune cells
ES2792849T3 (es) *	2014-02-10	2020-11-12	Univ Emory	Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
SG10202103475XA (en)	2014-12-02	2021-05-28	Prospect Chartercare Rwmc Llc	Methods and compositons for treating cancer

2015
- 2015-12-01 SG SG10202103475XA patent/SG10202103475XA/en unknown
- 2015-12-01 WO PCT/US2015/063267 patent/WO2016089916A1/en not_active Ceased
- 2015-12-01 JP JP2017529284A patent/JP2017537622A/ja active Pending
- 2015-12-01 CN CN201580074883.3A patent/CN107709353A/zh active Pending
- 2015-12-01 MX MX2017007272A patent/MX2017007272A/es unknown
- 2015-12-01 EP EP15865800.5A patent/EP3227317A4/en not_active Withdrawn
- 2015-12-01 EA EA201791210A patent/EA201791210A1/ru unknown
- 2015-12-01 CA CA2969714A patent/CA2969714A1/en not_active Abandoned
- 2015-12-01 KR KR1020177018139A patent/KR20180041087A/ko not_active Withdrawn
- 2015-12-01 BR BR112017011771A patent/BR112017011771A2/pt not_active Application Discontinuation
- 2015-12-01 US US14/956,299 patent/US9650428B2/en not_active Expired - Fee Related
- 2015-12-01 HK HK18110565.4A patent/HK1251862A1/zh unknown
- 2015-12-01 SG SG11201704519YA patent/SG11201704519YA/en unknown
- 2015-12-01 AU AU2015355084A patent/AU2015355084A1/en not_active Abandoned
- 2015-12-02 AR ARP150103939A patent/AR102879A1/es unknown
- 2015-12-02 TW TW104140317A patent/TW201636425A/zh unknown
- 2015-12-02 UY UY0001036418A patent/UY36418A/es not_active Application Discontinuation
2017
- 2017-05-09 US US15/590,961 patent/US20180072789A1/en not_active Abandoned
- 2017-06-01 IL IL252610A patent/IL252610A0/en unknown
- 2017-06-02 PH PH12017501031A patent/PH12017501031A1/en unknown

Also Published As

Publication number	Publication date
EA201791210A1 (ru)	2017-11-30
HK1251862A1 (zh)	2019-04-26
US20180072789A1 (en)	2018-03-15
US20160151490A1 (en)	2016-06-02
JP2017537622A (ja)	2017-12-21
PH12017501031A1 (en)	2017-11-27
SG10202103475XA (en)	2021-05-28
CN107709353A (zh)	2018-02-16
SG11201704519YA (en)	2017-07-28
BR112017011771A2 (pt)	2018-07-10
TW201636425A (zh)	2016-10-16
UY36418A (es)	2016-06-30
CA2969714A1 (en)	2016-06-09
US9650428B2 (en)	2017-05-16
EP3227317A1 (en)	2017-10-11
KR20180041087A (ko)	2018-04-23
AR102879A1 (es)	2017-03-29
EP3227317A4 (en)	2018-04-25
WO2016089916A1 (en)	2016-06-09
IL252610A0 (en)	2017-07-31
AU2015355084A1 (en)	2017-06-29

Publication	Publication Date	Title
PH12017501031A1 (en)	2017-11-27	Methods and compositions for treating cancer
PH12019500193A1 (en)	2019-07-29	Chimeric antigen receptors targeting bcma and methods of use thereof
MX2024010240A (es)	2024-09-11	Receptores de antigenos quimericos dirigidos a bcma y metodos de uso de estos.
MX2017013298A (es)	2018-06-19	Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b.
MX2023007045A (es)	2023-06-23	Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos.
PH12018502400A1 (en)	2019-04-08	Anti-tim-3 antibodies and methods of use thereof
PH12019501959A1 (en)	2020-07-06	Therapeutic rna
MX2019012223A (es)	2019-12-09	Anticuerpos anti-cd137 y metodos de uso de los mismos.
AU2018291128A1 (en)	2020-01-23	Anti-B-cell maturation antigen chimeric antigen receptors with human domains
ZA201708265B (en)	2025-04-30	Tigit-binding agents and uses thereof
WO2018098365A3 (en)	2018-07-12	Compositions and methods for tcr reprogramming using fusion proteins
GB2557123A (en)	2018-06-13	Modified cells and methods of therapy
GB2564823A (en)	2019-01-23	Compositions and methods for T-cell receptors reprogramming using fusion proteins
NZ743124A (en)	2022-11-25	Antibodies targeting fc receptor-like 5 and methods of use
EP3964527A3 (en)	2022-06-15	Combination therapy for cancer
WO2015109124A3 (en)	2015-09-24	Immunomodulatory agents
MX2017012939A (es)	2018-05-22	Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
MX2017001013A (es)	2018-02-21	Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1.
MY181834A (en)	2021-01-08	Treatment of cancer using humanized anti-bcma chimeric antigen receptor
EA201890294A1 (ru)	2018-07-31	Химерный полипептидный комплекс и способы его получения и применения
MY205850A (en)	2024-11-15	Proteins binding bcma, nkg2d and cd16
PH12017500918A1 (en)	2017-11-20	Antibodies against cd73 and uses thereof
MY181106A (en)	2020-12-17	Anti-lag3 antibodies and uses thereof
PH12017500022A1 (en)	2017-05-15	Carrier-antibody compositions and methods of making and using the same
BR112019004711A2 (pt)	2019-05-28	receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos